Format

Send to

Choose Destination
Am J Ther. 2014 May-Jun;21(3):e80-1. doi: 10.1097/MJT.0b013e3182456de7.

Hyperprolactinemia with aripiprazole: understanding the paradox.

Author information

1
1The Metabolic Clinic in Psychiatry, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India; and 2Department of Psychiatry, Kasturba Medical College, Manipal University, Manipal, India.

Abstract

Aripiprazole, due to its partial agonist activity at the D2 receptors, is often recommended as the drug of choice in patients who develop antipsychotic-induced hyperprolactinemia. We report a case of a female patient who developed hyperprolactinemia while on treatment with aripiprazole. This partial D2 agonistic activity of aripiprazole could be dose related, and hence, at higher doses, aripiprazole by itself can have dopamine antagonistic properties and hence cause prolactin system abnormalities.

PMID:
22357167
DOI:
10.1097/MJT.0b013e3182456de7
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center